Nishitha M. Reddy

Hematology
1301 Medical Center Dr Ste 3903
Nashville, TN 37232

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 107 publications

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.

Journal: Blood cancer journal
Published: January 07, 2025

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.

Journal: Blood advances
Published: May 22, 2024

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.

Journal: Cancer
Published: October 25, 2023

Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.

Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.

Journal: Blood advances
Published: September 17, 2023

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

Journal: Blood advances
Published: May 16, 2023

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.

Journal: Leukemia & lymphoma
Published: March 24, 2023

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.

Journal: American journal of hematology
Published: February 27, 2023

Is every pancreatic cancer patient a palliative care patient?

Is every pancreatic cancer patient a palliative care patient?

Journal: Annals of palliative medicine
Published: December 24, 2022

Postibrutinib relapse outcomes for patients with marginal zone lymphoma.

Postibrutinib relapse outcomes for patients with marginal zone lymphoma.

Journal: Blood advances
Published: July 25, 2022

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.

Journal: Journal of hematology & oncology
Published: May 30, 2022

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.

Journal: The Lancet. Oncology
Published: January 19, 2022

Exploiting Tumor Necrosis Factor Aberrations in Marginal Zone Lymphoma.

Exploiting Tumor Necrosis Factor Aberrations in Marginal Zone Lymphoma.

Journal: JCO precision oncology
Published: January 07, 2022
Showing 1-12 of 107

Last Updated: 09/26/2026